AstraZeneca And Daiichi Sankyo's ENHERTU Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors In DESTINY-PanTumor02 Phase II Trial
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated clinically meaningful survival in the DESTINY-PanTumor02 Phase II trial for patients with HER2-expressing advanced solid tumors. The trial showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months. The results support ongoing discussions with global regulatory authorities and reaffirm the potential role of ENHERTU as a tumor-agnostic therapy.
October 23, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's ENHERTU demonstrated promising results in a Phase II trial, which could potentially lead to regulatory discussions and approvals, positively impacting the company's stock.
The positive results from the Phase II trial of ENHERTU, a drug developed by AstraZeneca and Daiichi Sankyo, could lead to regulatory discussions and potential approvals. This could increase the value of AstraZeneca's stock as it indicates the company's strong pipeline and potential for future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100